Effect of Beraprost Sodium on Pulmonary Arteria Hypertension with Left Ventricular Systolic Dysfunction

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012961

Enrollment

Unknown

Registered

2017-10-12

Start date

2017-10-01

Completion date

Unknown

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arteria Hypertension with Left Ventricular Systolic Dysfunction

Interventions

Beraprost Sodium group:Beraprost Sodium

Routine treatment group:Routine medication

Eligibility

Sex/Gender

All

Age

59 Years to 72 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years old, male or female; 2. pulmonary artery systolic pressure by echocardiography = 30mmhg, and left ventricular ejection fraction <45%; 3. Willingness to accept this study.

Exclusion criteria

Exclusion criteria: 1. The shock patients; 2. The other type of pulmonary hypertension (idiopathic pulmonary hypertension; pulmonary hypertension by connective tissue diseases, drugs, thromboembolic, chronic lung disease, portal hypertension, congenital heart disease, etc.); 3. the severe hepatic insufficiency; 4. the hemorrhagic disease; 5. The pregnancy and lactation of the female; 6. Poor compliance, medication and follow-up were not on time.

Design outcomes

Primary

Measure	Time frame
pulmonary artery pressure;Left ventricular ejection fraction;6 minute walk distance;Major adverse cardiac events;	—

Countries

China

Contacts

Public ContactZhao Liang-ping

The Second Affiliated Hospital of Soochow University

zhaoliangping1234@aliyun.com+86 15262456676

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026